Table 1. Clinical characteristics of the 508 patients with human immunodeficiency virus infection.
| <195 days (n = 85) | 195–270 days (n = 174) | >270 days (n = 249) | |
|---|---|---|---|
| Age (years) | 41.5 ± 15.1 | 42.6 ± 15.2 | 42.5 ± 14.4 |
| Age ≥50 | 18 (21.2%) | 46 (26.4%) | 67 (26.9%) |
| Male | 71 (83.5%) | 159 (91.4%) | 224 (90.0%) |
| Timing of TB diagnosis | |||
| Pre-DOTS era | 46 (54.1%) | 101 (58.0%) | 152 (61.0%) |
| DOTS era | 39 (45.9%) | 73 (42.0%) | 97 (39.0%) |
| Comorbidity | 11 (12.9%) | 22 (12.6%) | 27 (10.8%) |
| Diabetic mellitus | 7 (8.2%) | 15 (8.6%) | 23 (9.2%) |
| Chronic obstructive pulmonary disease | 3 (3.5%) | 3 (1.7%) | 3 (1.2%) |
| Malignancy* | 3 (3.5%) | 5 (2.9%) | 1 (0.4%) |
| End-stage renal disease | 0 (0.0%) | 1 (0.6%) | 1 (0.4%) |
| Low income | 3 (3.5%) | 5 (2.9%) | 6 (2.4%) |
| Duration of anti-TB treatment (days)** | 182.2 ± 8.3 | 233.5 ± 23.7 | 317.3 ± 34.1 |
| Total duration of isoniazid administration** | 152.7 ± 49.9 | 178.6 ± 77.0 | 233.2 ± 110.7 |
| ≥240 days** | 0 (0.0%) | 33 (19.0%) | 173 (69.5%) |
| Total duration of rifamycin administration** | 155.6 ± 38.8 | 181.5 ± 60.6 | 237.0 ± 91.2 |
| ≥240 days** | 0 (0.0%) | 23 (13.2%) | 156 (62.7%) |
| Total duration of ethambutol administration** | 145.1 ± 42.4 | 180.1 ± 57.6 | 248.5 ± 81.0 |
| ≥240 days** | 0 (0.0%) | 21 (12.1%) | 177 (71.1%) |
| Total duration of pyrazinamide administration* | 80.4 ± 46.5 | 89.4 ± 69.2 | 106.0 ± 89.7 |
| ≥60 days | 59 (69.4%) | 107 (61.5%) | 162 (65.1%) |
| ≥90 days | 27 (31.8%) | 66 (37.9%) | 103 (41.4%) |
| 80% consistent with standards** # | 37 (43.5%) | 46 (26.4%) | 51 (20.5%) |
| Intensive phase (initial 60 days) | |||
| No. of days of isoniazid administration* | 52.0 ± 16.5 | 46.9 ± 19.1 | 44.6 ± 20.7 |
| No. of days of rifamycin administration** | 52.7 ± 10.3 | 46.6 ± 14.9 | 45.2 ± 16.6 |
| No. of days of ethambutol administration | 53.0 ± 9.6 | 50.7 ± 10.2 | 49.8 ± 12.5 |
| No. of days of pyrazinamide administration* | 47.6 ± 17.3 | 40.2 ± 20.3 | 40.6 ± 19.7 |
| Anti-HIV therapy during anti-TB treatment** | |||
| cART | 19 (22.4%) | 53 (30.5%) | 113 (45.4%) |
| Yes, but not cART | 17 (20.0%) | 38 (21.8%) | 67 (26.9%) |
| No | 49 (57.6%) | 83 (47.7%) | 69 (27.7%) |
| 2-year recurrence after anti-TB treatment | 5 (5.9%) | 9 (5.2%) | 4 (1.6%) |
cART, combination antiretroviral therapy; DOTS, directly observed therapy, short course; TB, tuberculosis.
Data are presented as numbers (%) or means ± SD.
*p < 0.05 and
**p < 0.001 between the 3 groups with different durations of anti-TB treatment according to one-way analysis of variance for continuous variables or the chi-square test for categorical variables.
#receiving isoniazid, rifamycin, ethambutol, and pyrazinamide for >48 days in the first 2 months, and isoniazid and rifamycin for >144 days in the first 6 months of anti-TB treatment.